
Product Data Sheet

Product Name: Cyclotriazadisulfonamide

Cat. No.: GC64068

Chemical Properties

Cas. No. 182316-44-5

Formula C₃₁H₃₉N₃O₄S₂

M.Wt 581.79

Solubility DMSO : 33.33 mg/mL (57.29 mM; Need ultrasonic and warming)

Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way[1][2].

Cyclotriazadisulfonamide (CADA) significantly decreases the amount of cell surface CD4 -the main receptor for HIV -without altering the expression of any other cellular receptor examined so far[1].Cyclotriazadisulfonamide (CADA) exhibits an EC₅₀ of 0.4 µg/mL for CD4 in MO-DC cells. Treatment of MO-DC with 10 µg/mL of CADA results in 83% downregulation of cell surface CD4, an effect that is similar to that observed for CADA treatment of CD4+ T cells[1].CADA prevents MT-4 cells from HIV-1 and SIV infection (EC₅₀ are 0.7 and 1.2 g/ml, respectively)[1].

[1]. Kurt Vermeire, et al. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res. 2008 May;6(3):246-56.

[2]. Victor Van Puyenbroeck, et al. Preprotein signature for full susceptibility to the co-translational translocation inhibitor cyclotriazadisulfonamide. Traffic. 2020 Feb;21(2):250-264.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA